HealthDay News - A contrast agent for certain MRIs
HealthDay News - Gadavist (gadobutrol) has been approved by the U.S. Food and Drug Administration as a contrast agent for people undergoing magnetic resonance imaging (MRI) of the central nervous system.
The gadolinium-based agent will help doctors detect lesions that affect the cell barrier between the brain and the blood stream, the FDA said in a news release. Approved for patients aged 2 years and older, the agent was evaluated in two clinical studies involving 657 patients.
Gadavast and similar agents include a boxed warning about the possibility of nephrogenic systemic fibrosis (NSF) in some people with kidney problems. NSF is a rare condition, characterized by thickening of the skin, that may lead to development of excess fibrous connective tissue in some internal organs. Gadavast, however, is thought to put users at lower risk of NSF, as compared to similar contrast agents, the FDA said.
The most common side effects reported during clinical testing of Gadavast included headache, nausea and hypersensitivity reactions, the agency said.
Gadavast is produced by Bayer Pharmaceuticals, based in Wayne, N.J.
More information: The FDA has more about its label warnings for MRI contrast agents.
Copyright © 2011 HealthDay. All rights reserved.
Could AI-Powered Abbreviated MRI Reinvent Detection for Structural Abnormalities of the Knee?
April 24th 2025Employing deep learning image reconstruction, parallel imaging and multi-slice acceleration in a sub-five-minute 3T knee MRI, researchers noted 100 percent sensitivity and 99 percent specificity for anterior cruciate ligament (ACL) tears.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
New Collaboration Offers Promise of Automating Prior Authorizations in Radiology with AI
March 26th 2025In addition to a variety of tools to promote radiology workflow efficiencies, the integration of the Gravity AI tools into the PowerServer RIS platform may reduce time-consuming prior authorizations to minutes for completion.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.